CAJ | 학술논문

目的探讨3-(4，5)-双甲基-2-噻唑-(2，5)-二苯基溴化四氮唑蓝(MTT)药敏试验法在指导临床胃癌及原发肝癌化疗中的作用。方法 50例胃癌和45例肝癌，分设对照组。在化疗前接受MTT药敏试验者，根据药敏结果指导化疗，对照组胃癌23例，肝癌20例，凭经验化疗。结果在胃癌中MTT敏感组有效率为82.6%(19/23)，MTT耐药组和对照组有效率分别为0(0/4)及47.8%(11/23)，差异有显著意义；肝癌MTT敏感组有效率为75%(15/20)，MTT耐药组和对照组有效率分别为0(0/5)及40%(8/20)有显著差异(P<0.01)。本研究体外药敏和体内疗效总符合率胃癌和肝癌分别为85.2%(19+4/27)和80%(15+5/25)。结论 MTT体外药敏试验在指导临床胃癌及原发肝癌的化疗中，具有满意的效果。
목적 탐토3-(4，5)-쌍갑기-2-새서-(2，5)-이분기추화사담서람(MTT)약민시험법재지도림상위암급원발간암화료중적작용。방법 50례위암화45례간암，분설대조조。재화료전접수MTT약민시험자，근거약민결과지도화료，대조조위암23례，간암20례，빙경험화료。결과 재위암중MTT민감조유효솔위82.6%(19/23)，MTT내약조화대조조유효솔분별위0(0/4)급47.8%(11/23)，차이유현저의의；간암MTT민감조유효솔위75%(15/20)，MTT내약조화대조조유효솔분별위0(0/5)급40%(8/20)유현저차이(P<0.01)。본연구체외약민화체내료효총부합솔위암화간암분별위85.2%(19+4/27)화80%(15+5/25)。결론 MTT체외약민시험재지도림상위암급원발간암적화료중，구유만의적효과。
Objective The predictive value of in vitro MTT assay forchemotherapy to stomach carcinoma and liver cancer patients was studied.Methods Of the 50 stomach carcinoma patients,27 had had MTT assay before chemotherapy.According to the result of the MTT assay,23 patients in MTT sensitive group received chemotherapy.The other 4 patients in MTT resistant group and 23 patients in the control group were given chemotheraphy according to clinician exparience,the same liver cancer 25 cases in MTT,5 in resistant group and 20 in the control group.Results The response rate in MTT sensitive group was 82.6% in stomach carcinoma,75% in liver cancer,respectively.There was statistically significant difference in the sensitive group as compared in the resistant group and in control group.Between in vitro and in vivo,the overall coincident rate was 85.2%(19+4/27) and 80%(15+5/25),respectively.ConclusionThe in vitro MTT assay can predict chemotherapy for stomach and liver carcinoma giving satisfactory results.